2021
Comparison of radiomic feature aggregation methods for patients with multiple tumors
Chang E, Joel MZ, Chang HY, Du J, Khanna O, Omuro A, Chiang V, Aneja S. Comparison of radiomic feature aggregation methods for patients with multiple tumors. Scientific Reports 2021, 11: 9758. PMID: 33963236, PMCID: PMC8105371, DOI: 10.1038/s41598-021-89114-6.Peer-Reviewed Original ResearchConceptsCox proportional hazards modelCox proportional hazardsProportional hazards modelBrain metastasesRadiomic featuresHazards modelProportional hazardsStandard Cox proportional hazards modelMultifocal brain metastasesMultiple brain metastasesNumber of patientsPatient-level outcomesHigher concordance indexRadiomic feature analysisRandom survival forest modelSurvival modelsDifferent tumor volumesMultifocal tumorsCancer outcomesMultiple tumorsMetastatic cancerConcordance indexTumor volumePatientsTumor types
2018
Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
Thomas A, Rosenblum M, Karimi S, DeAngelis LM, Omuro A, Kaley TJ. Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. CNS Oncology 2018, 07: 7-13. PMID: 29388793, PMCID: PMC6001559, DOI: 10.2217/cns-2017-0025.Peer-Reviewed Original ResearchConceptsMalignant gliomasRecurrence patternsDiffusion-weighted imaging abnormalitiesDiffusion-weighted imagingStandard clinical settingMG patientsImaging abnormalitiesMRI abnormalitiesPathologic findingsTumor recurrenceRadiographic patternsPathologic correlationBevacizumabClinical settingNecrosisPatientsRecurrenceRecent reportsTumorsGliomasAbnormalitiesLeptomeningealSurgery
2017
Overall survival in patients with glioblastoma before and after bevacizumab approval
Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm JH. Overall survival in patients with glioblastoma before and after bevacizumab approval. Current Medical Research And Opinion 2017, 34: 813-820. PMID: 29025274, DOI: 10.1080/03007995.2017.1392294.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBevacizumabFemaleGlioblastomaHumansKaplan-Meier EstimateMaleMiddle AgedRetrospective StudiesConceptsOverall survivalTreatment of patientsBevacizumab approvalProgressive glioblastomaGBM diagnosisUS population-based cancer registry dataPopulation-based cancer registry dataCox proportional hazards regressionLarge population-based studyOS of patientsApproval of bevacizumabGross total resectionKaplan-Meier analysisPopulation-based studyProportional hazards regressionLimited therapeutic optionsCancer registry dataAdjusted hazardAdult patientsMedian ageTotal resectionStudy cohortAggressive diseaseHazards regressionTherapeutic options
2016
Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma
Lin X, Lee M, Buck O, Woo K, Zhang Z, Hatzoglou V, Omuro A, Arevalo-Perez J, Thomas A, Huse J, Peck K, Holodny A, Young R. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma. American Journal Of Neuroradiology 2016, 38: 485-491. PMID: 27932505, PMCID: PMC5352508, DOI: 10.3174/ajnr.a5023.Peer-Reviewed Original ResearchLong-term survival in AIDS-related primary central nervous system lymphoma
Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro-Oncology 2016, 19: 99-108. PMID: 27576871, PMCID: PMC5193026, DOI: 10.1093/neuonc/now155.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyWhole brain radiotherapyPrimary central nervous system lymphomaCentral nervous system lymphomaAR-PCNSLNervous system lymphomaHD-MTXLong-term survivalMulticenter analysisSystem lymphomaAdvent of cARTLong-term disease-free survivalLonger progression-free survivalSan Francisco General HospitalHigh-dose methotrexateDisease-free survivalProgression-free survivalOptimal therapeutic approachTherapy-related factorsFirst-line interventionPost-cART eraLong-term toxicityAntiretroviral therapyBrain radiotherapyFavorable survivalSecond‐opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care
Hatzoglou V, Omuro AM, Haque S, Khakoo Y, Ganly I, Oh JH, Shukla-Dave A, Fatovic R, Gaal J, Holodny AI. Second‐opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care. Cancer 2016, 122: 2708-2714. PMID: 27219108, PMCID: PMC4992439, DOI: 10.1002/cncr.30083.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolDiagnostic ErrorsFemaleFollow-Up StudiesHumansImage Interpretation, Computer-AssistedInfantMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingNeoplasmsNeuroimagingObserver VariationPatient CarePhysiciansPrognosisRadiologistsReferral and ConsultationRetrospective StudiesTomography, X-Ray ComputedYoung AdultConceptsSecond-opinion interpretationsPatient managementMagnetic resonance imaging studySecond-opinion radiology reportsResonance imaging studyNational Cancer InstitutePatient ageNeuro-oncologistsCancer CenterDisease stageStudy criteriaCancer patientsClinical assessmentClinical impactNeck surgeonsRetrospective analysisHistopathologic analysisCancer InstituteImaging studiesRadiology reportsOutside reportsReference standardNeuroradiologistsSurgeonsDiscrepant reports
2015
Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence
Prager A, Martinez N, Beal K, Omuro A, Zhang Z, Young R. Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence. American Journal Of Neuroradiology 2015, 36: 877-885. PMID: 25593202, PMCID: PMC4731220, DOI: 10.3174/ajnr.a4218.Peer-Reviewed Original ResearchConceptsTreatment-related changesRecurrent tumorsHigh-grade gliomasSurgical resectionRecurrent high-grade gliomaLow relative cerebral blood volumeSubanalysis of patientsUtility of DWIRelative cerebral blood volumeTreatment-related effectsCerebral blood volumeWilcoxon rank sum testConventional MR imagingRank sum testConsecutive patientsHistopathologic evidenceMass lesionDSC perfusionRadiation therapyBlood volumeGrade gliomasPatientsLow perfusionTumorsDSC maps
2014
Methotrexate re-challenge for recurrent primary central nervous system lymphoma
Pentsova E, DeAngelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. Journal Of Neuro-Oncology 2014, 117: 161-165. PMID: 24481997, PMCID: PMC5256683, DOI: 10.1007/s11060-014-1370-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCentral Nervous System NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMethotrexateMiddle AgedNeoplasm Recurrence, LocalPrognosisRetreatmentRetrospective StudiesSalvage TherapyTreatment OutcomeConceptsPrimary CNS lymphomaKarnofsky performance scoreProgression-free survivalInitial diagnosisRecurrent primary central nervous system lymphomaPrimary central nervous system lymphomaMedian Karnofsky performance scoreMedian progression-free survivalCentral nervous system lymphomaObjective response rateNervous system lymphomaMedian OSCNS lymphomaFree survivalRecurrent diseaseSalvage treatmentFirst relapsePartial responsePCNSL patientsPrognostic factorsComplete responseMedian ageSystem lymphomaDisease relapseMedian timePretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification
Gupta A, Young R, Shah A, Schweitzer A, Graber J, Shi W, Zhang Z, Huse J, Omuro A. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification. Clinical Neuroradiology 2014, 25: 143-150. PMID: 24474262, PMCID: PMC4712066, DOI: 10.1007/s00062-014-0289-3.Peer-Reviewed Original Research
2013
Primary leptomeningeal lymphoma
Taylor JW, Flanagan EP, O'Neill BP, Siegal T, Omuro A, DeAngelis L, Baehring J, Nishikawa R, Pinto F, Chamberlain M, Hoang-Xuan K, Gonzalez-Aguilar A, Batchelor T, Blay JY, Korfel A, Betensky RA, Lopes MB, Schiff D. Primary leptomeningeal lymphoma. Neurology 2013, 81: 1690-1696. PMID: 24107866, PMCID: PMC3812109, DOI: 10.1212/01.wnl.0000435302.02895.f3.Peer-Reviewed Original ResearchConceptsPrimary leptomeningeal lymphomaPrimary CNS lymphomaLeptomeningeal lymphomaCNS lymphomaLeptomeningeal enhancementCSF cytologyMedian Eastern Cooperative Oncology Group performance statusRare formEastern Cooperative Oncology Group performance statusInternational Primary CNS Lymphoma Collaborative GroupIntra-CSF chemotherapyMedian overall survivalFavorable clinical responseCases of lymphomaOptimal diagnostic evaluationGene rearrangement studiesB-cell lymphomaMultifocal symptomsSalvage treatmentSystemic chemotherapyClinical responseOverall survivalPerformance statusMedian ageSystemic involvementBevacizumab for acute neurologic deterioration in patients with glioblastoma
Kaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncology 2013, 2: 413-418. PMID: 25054664, PMCID: PMC6136096, DOI: 10.2217/cns.13.40.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabBrainBrain NeoplasmsGlioblastomaHumansInpatientsKarnofsky Performance StatusMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalQuality of LifeRetrospective StudiesSurvival AnalysisTreatment OutcomeYoung AdultConceptsNeurologic dysfunctionNeurologic deteriorationOutpatient treatmentGlioblastoma patientsAcute neurologic dysfunctionDose of bevacizumabAcute neurologic deteriorationSevere neurologic dysfunctionQuality of lifeBevacizumab treatmentHospitalized patientsRetrospective reviewSteroid dependenceDexamethasone administrationRehabilitation admissionTumor locationPeritumoral edemaBevacizumabPatientsAbstractTextDysfunctionTreatmentGlioblastomaHospitalizationEdema
2012
Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer
Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J, Omuro A, Beal K, Seidman AD, Hudis CA, Fornier MN. Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer. The Breast Journal 2012, 18: 345-350. PMID: 22607041, DOI: 10.1111/j.1524-4741.2012.01246.x.Peer-Reviewed Original ResearchConceptsBrain metastasesOverall survivalBreast cancerDiagnosis of BMIncidence of BMMedian age 53 yearsRisk of BMTriple-negative breast cancerActuarial median survivalLimited overall survivalAge 53 yearsGroup of patientsPatterns of recurrenceSingle-institution studyNegative breast cancerElectronic medical recordsBM diagnosisMedian survivalMetastatic diseaseEntire cohortRetrospective studyTherapeutic optionsInstitutional databaseMedical recordsModern therapyAtypical and anaplastic meningiomas treated with bevacizumab
Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab. Journal Of Neuro-Oncology 2012, 109: 187-193. PMID: 22544653, DOI: 10.1007/s11060-012-0886-4.Peer-Reviewed Original ResearchConceptsProgression-free survivalVascular endothelial growth factor receptorAnaplastic meningiomasRadiographic responseMedian progression-free survivalBest radiographic responseEfficacy of bevacizumabMonths PFS rateEndothelial growth factor receptorKaplan-Meier statisticsActivity of bevacizumabEffective chemotherapeutic optionsAnti-angiogenic agentsTumor blood volumeMR perfusion studiesGrowth factor receptorPFS ratesStable diseaseBevacizumab therapyOverall survivalRANO criteriaRetrospective reviewSurgical optionsProspective studyAggressive tumorsLeptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy
Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy. Journal Of Thoracic Oncology 2012, 7: 382-385. PMID: 22089116, DOI: 10.1097/jto.0b013e3182398e4f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCranial IrradiationDose Fractionation, RadiationFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedLung NeoplasmsLymphatic MetastasisMaleMeningeal CarcinomatosisMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateConceptsNon-small cell lung cancerWhole brain radiotherapyCell lung cancerLeptomeningeal metastasesTyrosine kinase inhibitorsLandmark analysisIT chemotherapyBrain radiotherapyIntrathecal therapyMedian survivalLung cancerEGFR mutationsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsMedian age 59 yearsReceptor tyrosine kinase inhibitorsMedian overall survivalAge 59 yearsOptimal therapeutic approachSurvival of patientsDevastating complicationOverall survivalLeptomeningeal carcinomatosisRetrospective reviewRetrospective study
2011
Prophylactic intrathecal chemotherapy in primary CNS lymphoma
Sierra del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A, Kaloshi G, Elhallani S, Omuro A, Choquet S, Soussain C, Hoang-Xuan K. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. Journal Of Neuro-Oncology 2011, 106: 143-146. PMID: 21739169, DOI: 10.1007/s11060-011-0649-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansInjections, SpinalKarnofsky Performance StatusLomustineLymphomaMaleMethotrexateMethylprednisoloneMiddle AgedNeoplasm Recurrence, LocalNeuroprotective AgentsProcarbazineRetrospective StudiesYoung AdultConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaNervous system lymphomaProphylactic intrathecal chemotherapyIntrathecal chemotherapySystem lymphomaIntrathecal prophylaxisHigh-dose intravenous methotrexateRetrospective single-center studyObjective response ratePatterns of relapsePrimary CNS lymphomaProgression-free survivalSingle-center studyHigh intravenous dosesIntrathecal chemoprophylaxisIntravenous methotrexateProphylaxis withdrawalChemotherapy regimenCNS lymphomaSystemic chemotherapyKarnofsky indexOverall survivalIntravenous dosesMedian agePotential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma
Young R, Gupta A, Shah A, Graber J, Zhang Z, Shi W, Holodny A, Omuro A. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 2011, 76: 1918-1924. PMID: 21624991, PMCID: PMC3115805, DOI: 10.1212/wnl.0b013e31821d74e7.Peer-Reviewed Original ResearchConceptsEarly progressionMRI signsNegative predictive valuePredictive valueFinal diagnosisHigh negative predictive valueUseful MRI markerFisher's exact testSubependymal spreadSecond resectionRetrospective studyMass lesionSurgical specimensMRI markersPotential utilityClinical physiciansExact testMRI scansPatientsSubependymal enhancementLesionsGlioblastomaPseudoprogressionSignsDiagnosis
2010
Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma
Ducray F, Sierra del Rio M, Carpentier C, Psimaras D, Idbaih A, Dehais C, Kaloshi G, Mokhtari K, Taillibert S, Laigle-Donadey F, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. Journal Of Neuro-Oncology 2010, 101: 457-462. PMID: 20556480, DOI: 10.1007/s11060-010-0264-z.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, AlkylatingBrain NeoplasmsDacarbazineDNA MethylationDNA Modification MethylasesDNA Repair EnzymesDNA, NeoplasmFemaleFollow-Up StudiesHumansMaleOligodendrogliomaPolymerase Chain ReactionPromoter Regions, GeneticRetrospective StudiesSurvival RateTemozolomideTreatment OutcomeTumor Suppressor ProteinsConceptsProgression-free survivalAnaplastic oligodendroglial tumorsElderly patientsOverall survivalFront chemotherapyPartial responseMedian progression-free survivalLonger progression-free survivalInitial radiation therapyLonger overall survivalDuration of responseRate of respondersO6-methylguanine-DNA methyltransferase (MGMT) promoter methylationMethyltransferase promoter methylationEvaluable patientsStable diseaseConsecutive patientsConventional dosesRetrospective studyOptimal treatmentAnaplastic oligodendrogliomaRadiation therapyPatientsOligodendroglial tumorsTumor progressionNitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide
Kaloshi G, Sierra del Rio M, Ducray F, Psimaras D, Idbaih A, Laigle-Donadey F, Taillibert S, Houillier C, Dehais C, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. Journal Of Neuro-Oncology 2010, 100: 439-441. PMID: 20464625, DOI: 10.1007/s11060-010-0197-6.Peer-Reviewed Original ResearchConceptsLow-grade gliomasGrade gliomasProgressive low-grade gliomaTerms of PFSContrast enhancementEfficacy of nitrosoureasBetter PFSMedian PFSMedian OSObjective responseSalvage treatmentUpfront therapyMedian ageBetter prognosisInitial treatmentConventional radiotherapyChromosome 1p/19q codeletionNon-enhancing tumorResponse ratePatientsTemozolomidePure oligodendrogliomasPFSGliomasDisappointing resultsEfficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Journal Of Neuro-Oncology 2010, 100: 443-447. PMID: 20440540, PMCID: PMC3246379, DOI: 10.1007/s11060-010-0200-2.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerActive brain metastasesInitiation of bevacizumabSafety of bevacizumabProgression-free survivalBrain metastasesCell lung cancerCNS metastasisOverall survivalLung cancerCentral nervous system metastasesMedian progression-free survivalAccelerated FDA approvalActive CNS metastasesParenchymal brain metastasesProgressive brain metastasesMedian overall survivalNervous system metastasesAdditional safety dataPrimary brain tumorsHigh response rateIntra-tumoral hemorrhageBevacizumab safetyConcurrent anticoagulationCorticosteroid requirements
2008
Primary CNS lymphoma with intraocular involvement
Grimm S, McCannel C, Omuro A, Ferreri A, Blay J, Neuwelt E, Siegal T, Batchelor T, Jahnke K, Shenkier T, Hall A, Graus F, Herrlinger U, Schiff D, Raizer J, Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto F, Abrey L. Primary CNS lymphoma with intraocular involvement. Neurology 2008, 71: 1355-1360. PMID: 18936428, PMCID: PMC4109164, DOI: 10.1212/01.wnl.0000327672.04729.8c.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaOverall survivalOcular therapyIntraocular involvementCNS lymphomaCSF cytologyMedian Eastern Cooperative Oncology Group performance statusEastern Cooperative Oncology Group performance statusMedian progression-free survivalClinical ophthalmic examinationLocal ocular therapyCommon presenting symptomProgression-free survivalSite of progressionDiagnosis of lymphomaEyes 12Primary CNSFree survivalIntraocular lymphomaPresenting symptomBrain lymphomaImmunocompetent patientsOcular involvementPerformance statusRetinal biopsy